FREE Register Now

FREE Registration (First-come, First-served basis)

MET as a druggable target in solid tumors

A Talk by Qian Xie
Quillen College of Medicine, East Tennessee State University, Johnson City, US

Register to watch this content

By submitting you agree to the Terms & Privacy Policy
Watch this content now

About this talk

Genetic alteration of receptor tyrosine kinase (RTK) family is common in solid tumors. While many changes such as overexpression, mutation, and amplification are found to be associated to poor prognosis, targeted therapy against RTKs has become a new avenue for cancer therapeutics which have shown clinical efficacy. Our research has been focused on evaluating the MET RTK as a druggable target in glioblastoma, the most malignant type of brain tumor. Using a transgenic mouse model, we demonstrated that overexpressing MET and its ligand hepatocyte growth factor (HGF) along with p53 inhibition in neonatal mouse brain induced de novo glioma initiation. Moreover, the tumor cells isolated from the mouse model showed glioma stem cell property and were sensitive to MET inhibitors. These results suggest that HGF/MET axis elicits a driving force in gliomagenesis and is a druggable target for treating glioblastoma and other types of solid tumors.

Categories covered by this talk

Have you got yours yet?

Our All-Access Passes are a must if you want to get the most out of this event.

Check them out

Proudly supported by

Want to sponsor this event? Contact Us.

Loading content...

Loading content...